Translate
Aim Immunotech Inc.
About
Aim Immunotech Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 8 2026
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
May 7 2026
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
Apr 16 2026
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
Apr 13 2026
AIM ImmunoTech Provides Routine Update on Annual Filings
Apr 9 2026
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
Recent Videos
🔴🔴AIM 🇺🇸 $.28 AIM ImmunoTech Inc ⭐️⭐️⭐️Morningstar #analisistecnico #enbuscadelosmejoresprecios
Apr 11, 2026
🔴🔴AIM 🇺🇸 $.28 AIM ImmunoTech Inc ⭐️⭐️⭐️Morningstar
Apr 11, 2026
AIM ImmunoTech: My "Going Concern" Warning from Their 10-K
Mar 28, 2026
$AIM Stock Analysis: Patent News Sparks Parabolic Spike 🔥📈
Mar 18, 2026